

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7282167

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ADC THERAPEUTICS SA	10/22/2018
RECEIVING PARTY DATA	
Name:	MEDIMMUNE LIMITED
Street Address:	MILSTEIN BUILDING
Internal Address:	GRANTA PARK
City:	CAMBRIDGE
State/Country:	UNITED KINGDOM
Postal Code:	CB21 6GH
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17699065
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6086621277
Email:	resivigny@casimirjones.com
Correspondent Name:	CASIMIR JONES
Address Line 1:	2275 DEMING WAY
Address Line 2:	SUITE 310
Address Line 4:	MIDDLETON, WISCONSIN 53562
ATTORNEY DOCKET NUMBER:	MEWB-38133.302
NAME OF SUBMITTER:	LISA MUELLER
SIGNATURE:	/Lisa Mueller, Reg. No. 38978/
DATE SIGNED:	04/15/2022
Total Attachments: 14	
source=38133-251_Assignments-Exec#page1.tif	
source=38133-251_Assignments-Exec#page2.tif	
source=38133-251_Assignments-Exec#page3.tif	
source=38133-251_Assignments-Exec#page4.tif	

source=38133-251_Assignments-Exec#page5.tif
source=38133-251_Assignments-Exec#page6.tif
source=38133-251_Assignments-Exec#page7.tif
source=38133-251_Assignments-Exec#page8.tif
source=38133-251_Assignments-Exec#page9.tif
source=38133-251_Assignments-Exec#page10.tif
source=38133-251_Assignments-Exec#page11.tif
source=38133-251_Assignments-Exec#page12.tif
source=38133-251_Assignments-Exec#page13.tif
source=38133-251_Assignments-Exec#page14.tif

ASSIGNMENT OF INVENTION & PATENT RIGHTS

Parties

- (1) **FEINGOLD, JAY MARSHALL** c/o ADC Therapeutics America, Inc., 2711 Centerville Road, Suite 400, Wilmington, New Castle County, Delaware 19808, United States of America ("Inventor");
- (2) **ADC THERAPEUTICS AMERICA, INC.** a Delaware Corporation whose registered office address is at 251 Little Falls Drive, Wilmington, DE 19808, New Castle County, United States of America ("ADCT USA");
- (3) **ADC THERAPEUTICS SA** incorporated and registered in the Swiss Confederation and whose principal address is Route de la Corniche 3b, 1066 Epalinges, Switzerland ("ADCT SA"); and
- (4) **MEDIMMUNE LIMITED** incorporated and registered in England & Wales with company number 02451177 whose registered office is at Milstein Building, Granta Park, Cambridge, CB21 6GH ("MedImmune");

each of "ADCT SA" and "MedImmune" being together the "Assignees" as the context may indicate.

Agreed terms

1. Definitions

The definitions in this clause apply in this Assignment.

"Completion Applications" means the completion patent applications, short particulars of which are set out in Part 2 of the Schedule.

"Invention" means the inventions entitled DOSAGE REGIME, being the subject matter of the Priority Applications.

"Patent Applications" means the Priority Applications, the Completion Applications and any future applications linked by one or more priorities to the Priority Applications or the Completion Applications and all matter contained in such applications and any and all:

- (a) national and regional phase applications of all such applications; and
- (b) divisions, continuations and continuations-in-part of all such applications; and
- (c) patents that may be granted pursuant to any of the aforesaid applications for their full period, including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates.

"Priority Applications" means the priority patent applications, short particulars of which are set out in Part 1 of the Schedule.

2. Assignment

In consideration of the sum of £1 (sufficiency and receipt of which the Inventor, ADCT USA and ADCT SA each expressly acknowledge), the Inventor hereby assigns absolutely to ADCT USA all its right, title and interest, thereafter ADCT USA hereby assigns absolutely to ADCT SA all its right, title and interest, and thereafter ADCT SA hereby assigns absolutely to MedImmune a one half share in all its right, title and interest in all countries, regions and territories of the world in, to and arising from the Invention and, with effect from immediately prior to the filing of each, the Patent Applications, to the effect that all patents granted therefrom shall vest in and shall proceed jointly in the names of ADCT SA and MedImmune, and including (but not limited to):

- (a) in respect of the Invention and any invention that shall be disclosed in, and all matter that shall be contained in, any of the Patent Applications, the right to file applications, claim priority from such applications, and prosecute and obtain grant of patent or other intellectual property protection in respect of any country, region or territory in the world;
- (b) in respect of each and any Patent Application:
 - (i) the right to claim priority from and to prosecute and obtain grant of patents; and
 - (ii) the right to file divisional applications based on the Patent Applications and to prosecute and obtain grant of patent on each and any such divisional application;
- (c) the right to extend to, or register in or in respect of any country, region or territory in the world, each and any of the Patent Applications and to extend to or register in, or in respect of, any country, region or territory in the world any patent or other intellectual property protection granted on any of such applications;
- (d) the absolute entitlement to any patents granted pursuant to any Patent Application; and
- (e) the right to bring, make, oppose or defend claims or actions, appeal proceedings and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of the Inventions and the Patent Applications, whether occurring before on or after the date of this Assignment.

3. Further assurance

The Inventor, ADCT USA and ADCT SA shall, at the Assignees' joint cost, perform all further acts and things, and execute all further documents, required by law or which the Assignees requests to vest in the Assignees the full benefit of the right, title and interest assigned to the Assignees under this Assignment, including (but not limited to):

- (a) documents required to be signed by or on behalf of the Inventor, ADCT USA or ADCT SA in the course of any applications which relate to the Invention or to any inventions that shall be disclosed in any of the Patent Applications;
- (b) registration of ADCT SA or MedImmune as co-applicant for, or co-proprietor of, the Patent Applications; and

- (c) assisting the Assignees in obtaining, defending and enforcing any of the Patent Applications, and assisting with any other proceedings which may be brought by or against the Assignees by any third party or in the resolution of any question concerning the Invention, or the Patent Applications or any inventions that shall be disclosed in any of the Patent Applications.

4. Right to amend the Schedule

The Inventor, ADCT USA and the Assignees grant the firm of Mewburn Ellis LLP the right to insert in Part 3 of the Schedule to this Assignment any further identification of any existing or future patent applications in any countries, regions or territories of the world, which shall fall within the scope of clause 2 above, or as may be necessary or desirable in order to comply with the rules of a patent office for the recordal of this Assignment.

5. Counterparts

This Assignment may be executed in any number of counterparts, each of which when executed shall constitute an original of this Assignment, but all the counterparts shall together constitute the same agreement.

6. Governing law and jurisdiction

This Assignment is governed by the laws of England and Wales and subject to the exclusive jurisdiction of its courts.

Schedule: The Patent Applications

Part 1: Priority Applications

Country/region	Application No.	Application Date	Title
GB	1709439.2	14 June 2017	DOSAGE REGIME
GB	1709441.8	14 June 2017	DOSAGE REGIME
GB	1709440.0	14 June 2017	DOSAGE REGIME
GB	1709444.2	14 June 2017	DOSAGE REGIME
GB	1710496.9	30 June 2017	DOSAGE REGIME
GB	1710493.6	30 June 2017	DOSAGE REGIME

Assignment of invention and PCT/EP2018/065862 & PCT/EP2018/065873
RKA/FP7380009/7380017 & Patent 96 & 99 WO, Patents 97 & 98 WO

GB	1710495.1	30 June 2017	DOSAGE REGIME
GB	1710494.4	30 June 2017	DOSAGE REGIME
GB	1720541.0	08 December 2017	DOSAGE REGIME
GB	1720544.4	08 December 2017	DOSAGE REGIME
GB	1720542.8	08 December 2017	DOSAGE REGIME
GB	1720543.6	08 December 2017	DOSAGE REGIME
GB	1802679.9	20 February 2018	DOSAGE REGIME
GB	1803298.7	28 February 2018	DOSAGE REGIME
GB	1808473.1	23 May 2018	DOSAGE REGIME


Part 2: Completion Applications

Country/region	Application No.	Application Date	Title
WO	PCT/EP2018/065873	14 June 2018	DOSAGE REGIME
WO	PCT/EP2018/065862	14 June 2018	DOSAGE REGIME

Part 3: Identification of some, but not necessarily all, patent applications falling within the scope of clause 2 of this Assignment

Country/region	Application No.	Application Date	Title	Signature for Mewburn Ellis LLP

Executed by JAY MARSHALL FEINGOLD in
the presence of:




SIGNATURE OF WITNESS

NAME: CARYL HIRSCH

ADDRESS: 7001 Mallorca Cres Boca Raton, FL 33433

OCCUPATION:

DATE: 22 Oct 2018



SIGNATURE OF INVENTOR

Executed by ADC THERAPEUTICS

AMERICA, INC. acting

by _____, a director, in the
presence of:

SIGNATURE OF DIRECTOR

SIGNATURE OF WITNESS

NAME:

ADDRESS:

OCCUPATION:

DATE:

Executed by ADC THERAPEUTICS SA

acting by _____, an
authorized signatory, in the presence of:

SIGNATURE OF AN AUTHORIZED
SIGNATORY

SIGNATURE OF WITNESS

NAME:

ADDRESS:

OCCUPATION:

DATE:

Executed by **JAY MARSHALL FEINGOLD** in
the presence of:

SIGNATURE OF WITNESS

NAME:

ADDRESS:

OCCUPATION:

DATE:

SIGNATURE OF INVENTOR

Executed by **ADC THERAPEUTICS
AMERICA, INC.** acting by Chris Martin, a
director, in the presence of:

SIGNATURE OF WITNESS

NAME: *Dulce Gonçalves*

ADDRESS: *c/o ADC Therapeutics, Route de la Corniche 38, 1066 Epalinges, Switzerland*

OCCUPATION: *Head of Legal*

DATE: *22 Oct. 2018*

SIGNATURE OF DIRECTOR

Executed by **ADC THERAPEUTICS SA**
acting by Michael Forer, a director, in the
presence of:

SIGNATURE OF WITNESS

NAME: *Dulce Gonçalves*

ADDRESS: *c/o ADC Therapeutics, Route de la Corniche 38, 1066 Epalinges, Switzerland*

OCCUPATION: *Head of Legal*

DATE: *22 Oct. 2018*

SIGNATURE OF DIRECTOR

Executed by **MEDIMMUNE LIMITED** acting
by _____, an authorized
signatory, in the presence of:

SIGNATURE OF WITNESS

NAME:

ADDRESS:


OCCUPATION:

DATE:

SIGNATURE OF AN AUTHORIZED
SIGNATORY

Executed by **MEDIMMUNE LIMITED** acting
by Christopher Winter, an authorized
signatory, in the presence of:

CL Winter
SIGNATURE OF AN AUTHORIZED
SIGNATORY



B. INCE
SIGNATURE OF WITNESS

NAME: B. INCE

ADDRESS: 2 Riverside, Milstein Building, Granta Park, Cambridge, UK

OCCUPATION: Personal Assistant

DATE: 9th November 2018

ASSIGNMENT OF INVENTION & PATENT RIGHTS

Parties

- (1) **UNGAR, DAVID RODNEY** c/o ADC Therapeutics America, Inc., 2711 Centerville Road, Suite 400, Wilmington, New Castle County, Delaware 19808, United States of America (the "Inventor");
- (2) **ADC THERAPEUTICS AMERICA, INC.** a Delaware Corporation whose registered office address is at 251 Little Falls Drive, Wilmington, DE 19808, New Castle County, United States of America ("ADCT USA");
- (3) **ADC THERAPEUTICS SA** incorporated and registered in the Swiss Confederation and whose principal address is Route de la Corniche 3b, 1066 Epalinges, Switzerland ("ADCT SA"); and
- (4) **MEDIMMUNE LIMITED** incorporated and registered in England & Wales with company number 02451177 whose registered office is at Milstein Building, Granta Park, Cambridge, CB21 6GH ("MedImmune");

each of "ADCT SA" and "MedImmune" being together the "Assignees" as the context may indicate.

Agreed terms

1. Definitions

The definitions in this clause apply in this Assignment.

"**Completion Application**" means the completion patent applications, short particulars of which are set out in Part 2 of the Schedule.

"**Invention**" means the inventions entitled DOSAGE REGIME, being the subject matter of the Priority Applications.

"**Patent Applications**" means the Priority Applications, the Completion Application and any future applications linked by one or more priorities to the Priority Applications or the Completion Application and all matter contained in such applications and any and all:

- (a) national and regional phase applications of all such applications; and
- (b) divisions, continuations and continuations-in-part of all such applications; and
- (c) patents that may be granted pursuant to any of the aforesaid applications for their full period, including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates.

"**Priority Applications**" means the priority patent applications, short particulars of which are set out in Part 1 of the Schedule.

2. Assignment

In consideration of the sum of £1 (sufficiency and receipt of which the Inventor, ADCT USA and ADCT SA each expressly acknowledge), the Inventor hereby assigns absolutely to ADCT USA all its right, title and interest, thereafter ADCT USA hereby assigns absolutely to ADCT SA all its right, title and interest, and thereafter ADCT SA hereby assigns absolutely to MedImmune a one half share in all its right, title and interest in all countries, regions and territories of the world in, to and arising from the Invention and, with effect from immediately prior to the filing of each, the Patent Applications, to the effect that all patents granted therefrom shall vest in and shall proceed jointly in the names of ADCT SA and MedImmune, and including (but not limited to):

- (a) in respect of the Invention and any invention that shall be disclosed in, and all matter that shall be contained in, any of the Patent Applications, the right to file applications, claim priority from such applications, and prosecute and obtain grant of patent or other intellectual property protection in respect of any country, region or territory in the world;
- (b) in respect of each and any Patent Application:
 - (i) the right to claim priority from and to prosecute and obtain grant of patents; and
 - (ii) the right to file divisional applications based on the Patent Applications and to prosecute and obtain grant of patent on each and any such divisional application;
- (c) the right to extend to, or register in or in respect of any country, region or territory in the world, each and any of the Patent Applications and to extend to or register in, or in respect of, any country, region or territory in the world any patent or other intellectual property protection granted on any of such applications;
- (d) the absolute entitlement to any patents granted pursuant to any Patent Application; and
- (e) the right to bring, make, oppose or defend claims or actions, appeal proceedings and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of the Inventions and the Patent Applications, whether occurring before on or after the date of this Assignment.

3. Further assurance

The Inventor, ADCT USA and ADCT SA shall, at the Assignees' joint cost, perform all further acts and things, and execute all further documents, required by law or which the Assignees request to vest in the Assignees the full benefit of the right, title and interest assigned to the Assignees under this Assignment, including (but not limited to):

- (a) documents required to be signed by or on behalf of the Inventor, ADCT USA or ADCT SA in the course of any applications which relate to the Invention or to any inventions that shall be disclosed in any of the Patent Applications;
- (b) registration of ADCT SA or MedImmune as co-applicant for, or co-proprietor of, the Patent Applications; and

- (c) assisting the Assignees in obtaining, defending and enforcing any of the Patent Applications, and assisting with any other proceedings which may be brought by or against the Assignees by any third party or in the resolution of any question concerning the Invention, or the Patent Applications or any inventions that shall be disclosed in any of the Patent Applications.

4. Right to amend the Schedule

The Inventor, ADCT USA and the Assignees grant the firm of Mewburn Ellis LLP the right to insert in Part 3 of the Schedule to this Assignment any further identification of any existing or future patent applications in any countries, regions or territories of the world, which shall fall within the scope of clause 2 above, or as may be necessary or desirable in order to comply with the rules of a patent office for the recordal of this Assignment.

5. Counterparts

This Assignment may be executed in any number of counterparts, each of which when executed shall constitute an original of this Assignment, but all the counterparts shall together constitute the same agreement.

6. Governing law and jurisdiction

This Assignment is governed by the laws of England and Wales and subject to the exclusive jurisdiction of its courts.

Schedule: The Patent Applications

Part 1: Priority Applications

Country	Application No.	Application Date	Title
GB	1709440.0	14 June 2017	DOSAGE REGIME
GB	1709444.2	14 June 2017	DOSAGE REGIME
GB	1710495.1	30 June 2017	DOSAGE REGIME
GB	1710494.4	30 June 2017	DOSAGE REGIME
GB	1720542.8	08 December 2017	DOSAGE REGIME
GB	1720543.6	08 December 2017	DOSAGE REGIME
GB	1802679.9	20 February 2018	DOSAGE REGIME
GB	1808473.1	23 May 2018	DOSAGE REGIME


Part 2: Completion Application

Country/region	Application No.	Application Date	Title
WO	PCT/EP2018/065873	14 June 2018	DOSAGE REGIME


Part 3: Identification of some, but not necessarily all, patent applications falling within the scope of clause 2 of this Assignment

Country/region	Application No.	Application Date	Title	Signature for Mewburn Ellis LLP

Executed by **DAVID RODNEY UNGAR** in
the presence of:



SIGNATURE OF INVENTOR



SIGNATURE OF WITNESS

NAME: *Stacey A. Bararo*

ADDRESS: *430 Mountain Ave, Murray Hill*

OCCUPATION: *Office Manager*

DATE: *Oct 23, 2018*

Executed by **ADC THERAPEUTICS
AMERICA, INC.** acting by Chris Martin, a
director, in the presence of:

SIGNATURE OF DIRECTOR

SIGNATURE OF WITNESS

NAME:

ADDRESS:

OCCUPATION:

DATE:

Executed by **ADC THERAPEUTICS SA**
acting by Michael Forer, a director, in the
presence of:

SIGNATURE OF DIRECTOR

SIGNATURE OF WITNESS

NAME:

ADDRESS:

OCCUPATION:

DATE:

Executed by **MEDIMMUNE LIMITED** acting
by _____, an
authorized signatory, in the presence of:

SIGNATURE OF AN AUTHORIZED
SIGNATORY

SIGNATURE OF WITNESS

NAME:

ADDRESS:

OCCUPATION:

DATE:

Executed by **DAVID RODNEY UNGAR** in
the presence of:

SIGNATURE OF INVENTOR

SIGNATURE OF WITNESS


NAME:

ADDRESS:

OCCUPATION:

DATE:

Executed by **ADC THERAPEUTICS
AMERICA, INC.** acting by Chris Martin, a
director, in the presence of:



SIGNATURE OF DIRECTOR

SIGNATURE OF WITNESS


NAME: *Julio Gonzalez*

ADDRESS: *c/o ADC Therapeutics, Route de la Corniche 38, 1066 Epalinges, Switzerland*

OCCUPATION: *Head of Legal*

DATE: *22 Oct. 2018*

Executed by **ADC THERAPEUTICS SA**
acting by Michael Forer, a director, in the
presence of:



SIGNATURE OF DIRECTOR

SIGNATURE OF WITNESS

NAME: *Julio Gonzalez*

ADDRESS: *ADC Therapeutics, Route de la Corniche 38, 1066 Epalinges, Switzerland*

OCCUPATION: *Head of Legal*

DATE: *22 Oct. 2018*

Executed by **MEDIMMUNE LIMITED** acting
by _____, an
authorized signatory, in the presence of:

SIGNATURE OF AN AUTHORIZED
SIGNATORY

SIGNATURE OF WITNESS

NAME:

ADDRESS:


OCCUPATION:

DATE:

Executed by **MEDIMMUNE LIMITED** acting
by Christopher Winter, an authorized
signatory, in the presence of:

CL Winter

SIGNATURE OF AN AUTHORIZED
SIGNATORY



B. Ince

SIGNATURE OF WITNESS

NAME: B. INCE

ADDRESS: 2 Riverside, Milstein Building, Granta Park, Cambridge, UK

OCCUPATION: Personal Assistant

DATE: 9th November 2018